Coagulation Biomarkers for Atrial Fibrillation

Overseen By Quintrele Jones, MPH

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Tulane University

Disqualifiers: Coagulation disorders, Pregnancy, Kidney disease, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 4

20 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores the link between certain blood markers related to clotting and atrial fibrillation, a heart rhythm disorder. It also examines the impact of catheter ablation, a procedure targeting heart tissue to correct rhythm issues, on these markers. The study includes individuals with persistent or occasional atrial fibrillation who are scheduled for catheter ablation and have undergone a specific heart scan as part of their regular care. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to significant medical advancements.

Why are researchers excited about this trial?

Researchers are excited about the COAG-AF Pilot Study because it explores the potential for using coagulation biomarkers to better understand and manage atrial fibrillation (AF). Unlike traditional treatment options for AF, which typically involve medications like anticoagulants and antiarrhythmics, this study aims to identify specific biomarkers that could provide deeper insights into clotting processes and AF risk. This approach could lead to more personalized and precise treatment strategies, reducing the risk of stroke more effectively than current methods. By focusing on these biomarkers, researchers hope to pave the way for innovations that could improve patient outcomes and tailor treatments based on individual biological profiles.

Who Is on the Research Team?

Nassir Marrouche, MD

Principal Investigator

Tulane University

Are You a Good Fit for This Trial?

Inclusion Criteria

Patients diagnosed with persistent or paroxysmal AF.

Patients that are undergoing catheter ablation at Tulane University Medical Center.

Patients that had a cardiac MRI prescribed by their physician as part of their standard of care.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Baseline blood draw and cardiac MRI (LGE-MRI) scan performed prior to ablation

1 day

1 visit (in-person)

Ablation and Immediate Post-Ablation

Catheter ablation procedure with blood samples taken during and immediately after the procedure

1 day

1 visit (in-person)

Follow-up

Blood draws and monitoring of atrial fibrillation burden using ECG patch at 1 month and 3 months post-ablation

3 months

2 visits (in-person)

What Are the Treatments Tested in This Trial?

Who Is Running the Clinical Trial?

Tulane University

Lead Sponsor

Trials

129

Recruited

259,000+